Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived

Madrigal Pharmaceuticals Inc (MDGL) reports Q2 2026 earnings tomorrow, July 30, before market open, with analysts expecting a loss of $-2.55 per share. The central question is whether the company's flagship MASH treatment Rezdiffra can continue its commercial momentum and narrow losses faster than expected. With the stock up 8% year-to-date and trading near $547, investors will scrutinize revenue trajectory and guidance as MDGL navigates the critical early commercialization phase of its first approved product.

Part 1: Earnings Preview

Madrigal Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapies for metabolic and liver diseases, with its lead product Rezdiffra (resmetirom) approved for treating metabolic dysfunction-associated steatohepatitis (MASH). The company represents a pure-play opportunity in the emerging MASH treatment market, a condition affecting millions of patients with significant unmet medical need.

For Q2 2026 ending June, analysts expect MDGL to report a loss of $-2.55 per share on consensus estimates from 5 analysts, with a range from $-2.03 to $-3.01. The company most recently reported Q1 2026 results with an actual loss of $-3.25 per share. Compared to the same quarter last year when MDGL posted a loss of $-1.90 per share, the consensus implies a 34% wider loss year-over-year, reflecting the substantial commercial launch investments for Rezdiffra.

Three key themes define this earnings story:

Rezdiffra Commercial Traction: The primary focus is on second-quarter revenue performance for Rezdiffra, which received FDA approval in March 2024. Recent analyst commentary from Truist, Barclays, and UBS suggests the drug is outperforming early cautious outlooks, with BofA noting in November 2025 that Rezdiffra "outperforms early cautious outlook." Investors will scrutinize prescription trends, patient starts, and payer coverage dynamics to assess whether the launch is meeting or exceeding expectations.

Path to Profitability: With analysts projecting losses to narrow significantly—from $-7.45 per share in fiscal 2026 to positive $9.18 per share in fiscal 2027 (a 223% improvement)—the trajectory toward profitability is critical. The company's ability to scale revenue while managing operating expenses will determine whether this aggressive turnaround timeline is achievable. Recent data presented in May 2026 showing Rezdiffra reduces cardiovascular and liver-related risk markers could support broader adoption and faster revenue growth.

Competitive Positioning in MASH: The MASH treatment landscape is evolving rapidly, with Inventiva's competing therapy seeing a 50% surge in February 2026 on investor optimism. MDGL's ability to differentiate Rezdiffra's clinical profile, demonstrate real-world effectiveness, and capture market share will be crucial. Analysts have been actively revising targets, with Barclays initiating coverage in January 2026 with a $964 price target, suggesting significant confidence in the company's competitive position.

Leading analysts remain constructive heading into the release. Truist raised its price target to $709 in May 2026 while maintaining a Buy rating, while Barclays' $964 target represents the Street high. UBS, B. Riley, and Oppenheimer have all raised targets in recent months, reflecting growing confidence in the commercial trajectory. The consensus among 20 analysts shows 17 Strong Buy ratings with a mean price target of $669.50, implying 22% upside from current levels.

Part 2: Historical Earnings Performance

Madrigal's earnings history reveals highly volatile performance relative to estimates, with dramatic swings in both directions over the past four quarters. The company has alternated between significant beats and misses, making it difficult to establish a consistent pattern.

The most recent quarter (Q1 2026) showed improvement with a 10% beat, reporting a loss of $-3.25 versus the $-3.61 estimate. However, this followed two consecutive quarters of substantial misses: Q4 2025 delivered a staggering 6,525% miss (reporting $-2.57 against a $0.04 profit estimate), and Q3 2025 missed by 157% (reporting $-5.08 versus $-1.98 expected). The Q2 2025 quarter showed a strong 45% beat with a loss of $-1.90 against expectations of $-3.48.

The extreme volatility in estimate accuracy—particularly the Q4 2025 result where analysts expected a small profit but the company delivered a loss—suggests the market is still calibrating expectations around Rezdiffra's commercial launch dynamics. The wide misses in Q3 and Q4 2025 likely reflected higher-than-anticipated launch costs and slower initial uptake, while the subsequent Q1 2026 beat may indicate the company is gaining better control over its commercialization spending. Investors should expect continued volatility as the market refines its understanding of the revenue ramp and operating leverage trajectory.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

MDGL reports before market open, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Historical price action shows significant volatility around earnings, with an average absolute Day 0 move of 10.51% and Day +1 follow-through averaging 5.66%. The stock has demonstrated a tendency for large initial reactions, with six of the past eight earnings events producing Day 0 moves exceeding 7% in magnitude.

The direction has been mixed but recently more positive: the most recent report (May 2026) produced a +7.42% Day 0 gain, while the prior three quarters showed a -11.11% decline (February 2026), a +7.83% gain (November 2025), and a +8.59% gain (August 2025). The largest moves occurred in late 2024 during the early Rezdiffra launch phase, with October 2024 delivering a massive +20.10% Day 0 move followed by +23.23% on Day +1.

The Day +1 follow-through has been more muted on average (5.66%) but can be substantial, particularly when the initial reaction is positive. The November 2025 and October 2024 reports both saw strong continuation, while other quarters showed reversals or consolidation. The wide Day 0 ranges—averaging 11.04%—indicate high intraday volatility regardless of closing direction, suggesting investors should prepare for significant price swings in both directions as the market digests results and guidance.

Part 2.2: Options Market Expected Move

The options market is pricing a 5.04% expected move for the upcoming earnings, which is substantially below the 10.51% average absolute Day 0 move from recent history. This suggests options traders may be underpricing potential volatility, particularly given MDGL's pattern of double-digit moves in five of the past eight reports. The $27.54 expected move implies a trading range of $519.34 to $574.42, which may prove conservative if the company delivers significant guidance surprises on the path to profitability.

Part 3: What Analysts Are Saying

Analyst sentiment on MDGL is overwhelmingly bullish, with the consensus rating at 4.70 out of 5.00—firmly in Strong Buy territory. The current breakdown shows 17 Strong Buy ratings, zero Moderate Buys, 3 Hold ratings, and zero Sell ratings among 20 analysts covering the stock. This represents an improved sentiment trend, with Strong Buy recommendations increasing from 16 to 17 over the past month while the average recommendation ticked up from 4.68 to 4.70.

The mean price target of $669.50 implies 22% upside from the current price of $546.88, with a wide range of expectations spanning from a low target of $553 (just 1% upside) to a high target of $964 (76% upside). The high target from Barclays reflects particularly aggressive optimism about Rezdiffra's commercial potential and the company's ability to capture the MASH treatment market.

Recent analyst activity has been notably positive, with multiple firms raising price targets in 2026. Truist lifted its target to $709 in May, Barclays initiated coverage with the Street-high $964 target in January, and B. Riley upgraded to Buy from Neutral in February while raising its target to $422. Even previously cautious BofA Securities upgraded from Underperform to Neutral in November 2025, citing Rezdiffra's better-than-expected performance. The concentration of Strong Buy ratings and the improved sentiment trend suggest analysts see the current valuation as attractive relative to the company's growth trajectory, particularly as it approaches the critical inflection point toward profitability in fiscal 2027.

Part 4: Technical Picture

MDGL enters earnings with strong technical momentum across all timeframes. The Barchart Technical Opinion currently stands at 100% Buy, a significant strengthening from 88% Buy one week ago and 32% Buy one month ago. This dramatic improvement in the signal reflects accelerating bullish momentum as the stock has climbed steadily into the earnings release.

Timeframe Analysis:

• Short-term (100% Buy): Strong buy signal indicates robust near-term momentum heading into the report
• Medium-term (100% Buy): Bullish reading confirms the uptrend is well-established across intermediate timeframes
• Long-term (100% Buy): Maximum buy signal suggests the longer-term trend structure remains firmly positive

Trend Characteristics: The trend is characterized as Soft but Strengthening, indicating momentum is building but may not yet be fully mature, leaving room for further acceleration if results exceed expectations.

The stock is trading at $546.88, positioned above all key moving averages: the 5-day ($544.96), 10-day ($544.39), 20-day ($542.07), 50-day ($517.82), 100-day ($508.48), and 200-day ($506.73). This complete alignment with price above all major moving averages is a classically bullish setup, with the shorter-term averages trending above longer-term averages in proper sequence.

The technical picture is supportive heading into earnings, with the stock in a clear uptrend and no overhead resistance from moving averages. The 8% year-to-date gain and recent acceleration above the $540 level suggest buyers are positioning ahead of the release. However, the "Soft" trend strength designation and the stock's history of volatile post-earnings moves warrant caution—while the setup is constructive, the technical momentum alone may not be sufficient to cushion a disappointing result. The 5.6% cushion above the 50-day moving average provides some support, but given MDGL's tendency for 10%+ earnings moves, a miss could quickly reverse the recent gains. Conversely, a strong beat with positive guidance could propel the stock toward the analyst consensus target zone near $670.